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Background: Carbapenem-resistant Enterobacteriaceae 
pose a serious threat to public health worldwide, and 
the role of companion animals as a reservoir is still 
unclear. Aims: This 4-month prospective observational 
study evaluated carriage of carbapenem-resistant 
Enterobacteriaceae at admission and after hospitalisa-
tion in a large referral hospital for companion animals 
in Switzerland. Methods: Rectal swabs of dogs and cats 
expected to be hospitalised for at least 48 h were taken 
from May to August 2018 and analysed for the pres-
ence of carbapenem-resistant Enterobacteriaceae using 
selective agar plates. Resistant isolates were further 
characterised analysing whole genome sequences for 
resistance gene and plasmid identification, and ad hoc 
core genome multilocus sequence typing. Results: This 
study revealed nosocomial acquisition of  Escherichia 
coli  harbouring the carbapenemase gene  blaOXA-181, 
the pAmpC cephalosporinase gene  blaCMY-42  as well 
as quinolone resistance associated with  qnrS1  and 
mutations in the topoisomerases II (GyrA) and IV (ParC). 
The blaOXA-181 and qnrS1 genes were identified on a 51 kb 
IncX3 plasmid and  blaCMY-42  on a 47 kb IncI1 plasmid. 
All isolates belonged to sequence type ST410 and 
were genetically highly related. This  E. coli  clone was 
detected in 17 of 100 dogs and four of 34 cats after hos-
pitalisation (21.6%), only one of the tested animals hav-
ing tested positive at admission (0.75%). Two positive 
animals were still carriers 4 months after hospital dis-
charge, but were negative after 6 months. Conclusions: 
Companion animals may acquire carbapenemase-
producing  E. coli  during hospitalisation, posing the 
risk of further dissemination to the animal and human 
population and to the environment.
Introduction
Companion animals nowadays not only share the own-
er’s home environment but also benefit from intensive 
veterinary care in case of serious illness. Veterinary 
referral hospital environments are similar to human 
hospitals in that animal patients face similar risks of 
developing nosocomial infections.
Bacterial infections in dogs and cats are frequently 
treated with critically important antimicrobials such as 
fluoroquinolones or cephalosporins. In very rare cases, 
even the last resort antibiotics of human medicine 
such as carbapenems may be used in companion ani-
mals in Switzerland to treat infections refractory to any 
other standard antimicrobial used in veterinary medi-
cine (Ordinance on Veterinary Medicinal Products, SR 
812.212.27, Art. 6).
Such treatments pose the risk of selecting resistance 
to these classes of antibiotics in Enterobacteriaceae 
through the acquisition of plasmid-mediated cephalo-
sporinase genes (e.g.  bla  CTX-M,  bla  CMY) and fluoroqui-
nolones resistance genes (e.g.  qnr,  aac-(6)-Ib-cr), but 
also through chromosomal mutations in the promotor 
region of the AmpC β-lactamase and in the quinolone 
resistance-determining region (QRDR) of the topoi-
somerases II (GyrA) and IV (ParC) [1,2]. Resistances 
to carbapenems have also emerged in  Escherichia 
coli and Klebsiella pneumoniae  [3]. Three main groups 
of carbapenemases are referenced according to the 
Ambler classification: class A (e.g. KPC), class B (IMP, 
VIM, NDM) and class D (e.g. OXA) [4]. Among the 
OXA carbapenemases, OXA-48-like ones have been 
described as phantom carbapenemases since they 
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may be difficult to detect using phenotypic susceptibil-
ity testing [5].
Until now, animals were considered to play a minor role 
in the dissemination of OXA-48-like carbapenemases 
[6], but reports of sporadic infections in dogs caused 
by carbapenemase-producing (CP) Enterobacteriaceae 
in Europe [7,8], in the United States (US) [9] and in 
Northern Africa [10] suggest that companion ani-
mals may represent an unsuspected reservoir of car-
bapenem-resistant bacteria. Recently, hospitalised 
companion animals in Italy were found to acquire car-
bapenem-resistant bacteria such as Acinetobacter spp. 
[11]. Nonetheless, very little is known about carriage 
and dynamics of CPE in dogs and cats before and after 
hospitalisation.
Figure 1 
Temporal acquisition and carriage of carbapenemase-producing Escherichia coli ST410, Switzerland, May–August 2018 
(n = 24)
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Shapes in green: test negative for CP E. coli carriage; shapes in red: test positive for CP E. coli carriage. Blue dotted line: time line of screened 
animals; grey dashed line: animals which were not resampled.
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Here, we characterised by whole genome sequenc-
ing (WGS) CP  E. coli  isolated from cats and dogs 
at admission and after hospitalisation to a large 
veterinary referral hospital in Switzerland, identifying 
their antimicrobial resistance genes (ARG) and mobile 
genetic elements (MGE) as well as the phylogenetic 
relationship among the isolates.
Methods
Study design and sampling
This study was part of a larger prospective study which 
included three large veterinary referral clinics and two 
smaller veterinary practices in Switzerland. The pre-
sent prospective observational study was performed 
at a university referral hospital with a 24/7 emergency 
service. The hospital provides advanced medical care 
for 6,000 dogs and cats annually. Dogs and cats were 
included irrespective of their underlying problems and 
previous treatments if they were expected to be hospi-
talised for at least 48 h and the owner gave informed 
consent. All animals presented here were recruited 
via the emergency service of the hospital. During the 
enrolment period of 4 months (1 May–31 August 2018), 
ca 2,000 animals were treated at the hospital and 134 
of them fulfilled the study criteria and were screened.
Rectal swabs were collected in awake animals at 
admission to the hospital and at discharge, using 
polyurethane foam culture swabs with Ames transport 
medium (BBL CultureSwabs). If available, animals posi-
tive at discharge were retested once or twice within 36 
to 166 days after their discharge of the clinic.
Isolation and identification of the strains
Swabs were placed into 5 mL of Luria-Bertani (LB) 
broth for overnight enrichment at 37 °C. A loopful 
of the culture was streaked onto CHROMID OXA-48 
Table 1
Demographic, hospitalisation and antimicrobial treatment details of dogs and cats positive for OXA181-
producing Escherichia coli ST410, Switzerland, May–August 2018 (n = 21)
Parameter Dogs (n = 17) Cats (n = 4)
Age median in years (IQR) 7.0 (4.0–9.0) 4.5 (2.3–10.5)
Weight median in kg (IQR) 16.6 (7.8–34) 4.2 (3.0–5.7)
Sex
Female (entire/neutered) 9 (5/4) 2 (0/2)
Male (entire/neutered) 8 (6/2) 2 (1/1)
Diagnoses
Gastrointestinal disease 7 1
Neurological disease 5 0
Urinary tract disease 2 2
Other 3 1
Hospitalisation days; median (IQR) 4 (3–5) 5 (1.8–8.3)
ICU days; median (IQR) 3 (1–5) 2.3 (1.5–8.6)
Antimicrobial pre-treatmenta
Yes 4 1
No 11 3
Unknown 2 0
Antimicrobial treatment during hospitalisation
Yes 14 3
No 3 1
Antimicrobials used during hospitalisationb
Ampicillin/sulbactam 9 3
Cefazolin 1 1
Clindamycin 2 0
Doxycycline 1 0
Enrofloxacin 1 0
Metronidazole 1 0
Sulfamethoxazole/trimethoprim 1 0
Amoxicillin/clavulanic acid 1 0
ICU: intensive care unit; IQR: interquartile range.
a Antimicrobials used for pre-treatments (i.e. prior to presentation/referral) were amoxicillin/clavulanic acid (n = 2), amoxicillin (n = 1), 
enrofloxacin (n = 1) and metronidazole (n = 1).
b Includes mono- and combination therapy.
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and CHROMID CARBA (Biomérieux SA, Marcy-l’Étoile, 
France) selective plates, which were incubated at 37 °C 
for 24 h under aerobic conditions.
Colonies were sub-cultivated onto trypton soy agar 
plates containing 5% sheep blood (TSA-S) (Becton 
and Dickinson Company, Franklin Lakes, US) and iden-
tified to the species level by matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrom-
etry (MALDI-TOF MS) (Bruker Daltonics GmbH, Bremen, 
Germany).
Biochemical and molecular tests
Carbapenemase production was detected using the 
Blue-Carba test [12]. Before WGS, carbapenemase-pro-
ducing isolates were tested for the presence of bla OXA-
48-like genes by PCR [5].
Antimicrobial susceptibility testing
Minimal inhibitory concentrations (MIC) of 16 antimi-
crobials (ampicillin, cefepime, cefotaxime, ceftazidime, 
chloramphenicol, ciprofloxacin, colistin, ertapenem, 
gentamicin, imipenem, meropenem, nalidixic acid, sul-
famethoxazole, tetracycline, tigecycline and trimetho-
prim) were determined by broth microdilution using 
Sensititre EUVSEC and EUVSEC2 plates (Thermo Fisher 
Scientific, Waltham, US) and following the guide-
lines from the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) [13]. MIC results were 
interpreted using the EUCAST criteria, except for nali-
dixic acid, sulfamethoxazole and tetracycline, for which 
criteria from the Clinical and Laboratory Standards 
Institute (CLSI) were used [14].
Figure 2
Phylogenetic neighbour-joining tree of all carbapenemase-producing Escherichia coli of ST410 isolated from animals 
hospitalised in a companion animal clinic (n = 24) and others available in GenBank (n = 7), Switzerland, May–August 2018
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The tree was generated and drawn using SeqSphere+ (v. 401, Rindom GmbH, Münster, Germany) for the comparison of 3,778 genes from the 
core genome (cgMLST) of the genomic sequences.
Blue: isolates from animals; green: isolates from humans; orange: isolates from the environment.
E. coli isolates used for the comparison were carrying the following resistance genes to β-lactams, cephalosporins and carbapenems: 
CP018965: bla KPC-2, bla OXA-1, bla CTX-M-15; CP023899: bla CTX-M-15, bla TEM-1B; CP024801: bla CMY-2, bla NDM-5, bla TEM-1B, bla CTX-M-15, bla OXA-1; CP027205: 
bla CMY-2, bla TEM-1B, bla CTX-M-65, bla NDM-5; CP026473: bla CMY-2, bla NDM-5, bla TEM-1B, bla CTX-M-15, bla OXA-1, bla OXA-181; CP029630: bla TEM-1A, bla OXA-9, bla 
CTX-M-15, bla NDM-1; CP031653: bla NDM-5, bla CMY-42, bla TEM-190.
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Whole genome sequencing and in silico 
analysis
Total DNA from OXA-48-like-positive strains was 
isolated using the DNeasy Blood and Tissue Kit 
(Qiagen, Venlo, the Netherlands), and purified using 
the AMPure XP paramagnetic bead-based chemis-
try (Beckmann Coulter, Brea, US). All CP  E. coli  were 
sequenced (2 × 150 bp paired-end) using the Illumina 
HiSeq technology (Illumina Inc, San Diego, US) at the 
Eurofins Institut (Konstanz, Germany). The genomic 
DNA of strain AR24.2b was additionally sequenced 
with MinION on a R9.4 Spot On flow cell using the 
library preparation kit SQK-LSK108 (Oxford Nanopore 
Technologies (ONT), Oxford, United Kingdom (UK)). 
Genome assembly of all strains was performed using 
SPAdes (v3.12.0) and the obtained contigs were used 
for in silico analysis. The genome assembly of strain 
AR24.2b was performed by Unicycler (v0.4.4), using 
both long (ONT) and short reads (Illumina), as well as 
by CANU (v1.7) that only uses the ONT long reads. The 
obtained scaffolds were polished by read-mapping 
with paired-end Illumina reads using Pilon (v1.22) 
and with Geneious software v10.1.3 (Biomatters Ltd, 
Auckland, New Zealand). Annotation was performed 
with PROKKA v1.12. The paired-end reads of all CP  E. 
coli strains were mapped to the final annotated plasmid 
sequences of AR24.2b. Online tools available at the 
Center for Genomic Epidemiology (Technical University 
of Denmark DTU, Lyngby, Denmark) were used to 
detect known ARG (ResFinder 3.0) to determine incom-
patibility (Inc) groups of the plasmids, (PlasmidFinder 
1.3) and for multilocus sequence typing (MLST 2.0). 
Table 2
Minimum inhibitory concentrations of 16 antibiotics for carbapenemase-producing Escherichia coli isolates of ST410 from 
cats and dogs, Switzerland, May–August 2018 (n = 24)
MIC of antibiotics in μg/mLa and 
resistance breakpointsb in 
parentheses
AMP 
(> 8) 
CHL 
(> 8) 
CIP 
(> 0.5) 
COL 
(> 2) 
ETP 
(> 0.5) 
FEP 
(> 4) 
FOT 
(> 2) 
GEN 
(> 4) 
IMI 
(> 4) 
MERO 
(> 8) 
NAL 
(≥ 32) 
SMX 
(≥ 512) 
TAZ 
(> 4) 
TET 
(≥ 16) 
TGC 
(> 2) 
TMP 
(> 4) 
Strain Animal Time point of isolation
AR8.2b Dog 8 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 1 0.5 > 128 16 > 128 4 0.5 0.5
AR10.2b Dog 10 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 32 > 128 4 ≤ 0.25 1
AR17.2b Dog 17 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 0.5
AR22.1 Dog 22 Admission > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 1 0.5 > 128 16 > 128 4 0.5 0.5
AR22.2 Dog 22 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 16 > 4 1 0.5 0.5 > 128 16 > 128 4 0.5 0.5
AR24.2b Dog 24 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.25 > 128 32 > 128 4 ≤ 0.25 2
AR25.2 Dog 25 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 8 0.5 1
AR26.2c Dog 26 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 1 0.5 > 128 16 > 128 4 0.5 1
AR31.2a Dog 31 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 1
AR33.2a Dog 33 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 1
AR44.2 Dog 44 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 0.5
AR46.2b Dog 46 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.25 > 128 16 > 128 4 ≤ 0.25 1
AR62.2 Dog 62 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 1
AR76.2 Cat 76 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 1
AR81.2 Cat 81 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 0.5 1
AR89.2b Dog 89 Discharge > 64 ≤ 8 > 8 ≤ 1 2 2c > 4 ≤ 0.5 0.5 0.5 > 128 16 2c 4 0.5 0.5
AR94.2b Dog 94 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 8 > 4 ≤ 0.5 1 0.5 > 128 ≤ 8 > 128 4 ≤ 0.25 0.5
AR96.2a Cat 96 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 1 0.5 0.5 > 128 16 > 128 8 0.5 0.5
AR135.2a Dog 135 Discharge > 64 ≤ 8 > 8 ≤ 1 > 2 16 > 4 ≤ 0.5 0.5 1 > 128 16 > 128 8 0.5 0.5
AR144.2 Dog 144 Discharge > 64 ≤ 8 > 8 ≤ 1 2 2c > 4 ≤ 0.5 0.5 0.25 > 128 16 1 > 64 ≤ 0.25 1
AR145.2 Cat 145 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.25 > 128 16 > 128 4 ≤ 0.25 1
AR148.2 Dog 148 Discharge > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.5 > 128 16 > 128 4 ≤ 0.25 1
AR76.3 Cat 76 Follow-up > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.25 0.25 > 128 16 > 128 4 ≤ 0.25 1
AR96.3a Cat 96 Follow-up > 64 ≤ 8 > 8 ≤ 1 2 8 > 4 ≤ 0.5 0.5 0.25 > 128 16 > 128 4 ≤ 0.25 1
Number of non-susceptible strains 24 0 24 0 24 24 24 0 0 0 24 0 23 1 0 0
AMP: ampicillin; CHL: chloramphenicol; CIP: ciprofloxacin; COL: colistin; ETP: ertapenem; FEP: cefepime; FOT: cefotaxime; GEN: gentamicin; 
IMI: imipenem; MERO: meropenem; MIC: minimum inhibitory concentration; NAL: nalidixic acid; SMX: sulfamethoxazole; TAZ: ceftazidime; 
TET: tetracycline; TGC: tigecycline; TMP: trimethoprim.
a MICs highlighted in bold indicate resistance.
b The resistance breakpoints presented here are those for E. coli from the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) [13], except for nalidixic acid, sulfamethoxazole and tetracycline, for which breakpoints from the Clinical and Laboratory 
Standards Institute (CLSI) [14] were used.
c The MIC values of 2 μg/mL for cefepime and for ceftazidime were above the susceptible EUCAST breakpoint (S ≤ 1 μg/mL) and within the 
intermediate range (non-susceptible).
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Transposable elements present in the plasmids were 
identified using ISfinder (https://isfinder.biotoul.fr/). 
Blast ring image generator (BRIG) was used to gener-
ate circular map comparisons of plasmids (based on 
BLASTn) [15]. Comparison with closely related plasmids 
from the National Center for Biotechnology Information 
(NCBI) was achieved using the NCBI tool BLASTn 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed 
November 2018).
Phylogenetic analyses
An ad hoc core genome multilocus sequence typing 
(cgMLST) scheme was created using SeqSphere+ (v. 
401, Rindom GmbH, Münster, Germany). The  E. coli  of 
sequence type (ST) 410 from a dog in the UK (GenBank 
accession number CP031653) was defined as the ref-
erence genome from which 4,177 coding regions of 
genes were extracted by the cgMLST Target Finder 
v1.4. The contigs obtained from SPAdes of all 24 CP E. 
coli  in this study, together with the reference genome 
and with six other genomes of  E. coli  ST410 isolated 
from humans or from the environment and published 
in GenBank (GenBank accession numbers CP029630, 
CP027205, CP026473, CP024801, CP023899 and 
CP018965), were loaded and searched for the 4,177 
gene targets using built-in BLAST. Overall, 3,778 genes 
were shared among all isolates, which we defined as 
the core genome. The visualisation of the phyloge-
netic distance was achieved using the allelic profile of 
all strains to generate a neighbour-joining tree using 
SeqSphere+ with the parameters ‘pairwise ignoring 
missing values; % columns difference’ for the distance 
calculation.
Ethical statement
The study protocol was approved by the national eth-
ics committee (BE 16/18) and signed informed consent 
was obtained from the owners before enrolment of the 
animals in the study.
Results
Occurrence of carbapenemase-
producing Escherichia coli
Rectal swabs were taken from 100 dogs and 34 cats 
at admission to a large veterinary referral clinic in 
Switzerland between 1 May and 31 August 2018. 
Carriage of CP E. coli was detected in only one dog and 
none of the cats at admission (0.75%; 95% confidence 
interval (CI): 0–2.2).
In contrast, 17 of 76 dogs and four of 21 cats that were 
resampled at discharge were found to harbour CP  E. 
coli  (21.6%; 95% C: 13.4–29.8) indicating nosocomial 
acquisition of the bacteria. The 37 remaining animals 
were not available for resampling (n = 22) or deceased 
(n = 15).
Table 3
Characteristics of the carbapenemase-producing Escherichia coli isolates, Switzerland, May–August 2018 (n = 24)
Strains STa Resistance phenotypeb
Resistance genesc and 
mutationsd Localisation
e
AR8.2b; AR10.2b; AR17.2b; AR22.1; AR22.2; AR24.2b; 
AR25.2; AR26.2c; AR31.2a; AR33.2a; AR44.2; AR46.2b; 
AR62.2; AR76.2; AR76.3; AR81.2; AR94.2b; AR96.2a; 
AR96.3; AR135.2a; AR145.2; AR148.2 (n = 22)
410 AMP-CIP-ETP-FEP-FOT-NAL-TAZ
blaCMY-42, sugE Plasmid IncI1, 47-kb
blaOXA-181, qnrS1 Plasmid IncX3, 51-kb
GyrA (Ser83Leu, 
Asp87Asn); ParC (Ser80Ile) Chromosome
AR89.2b (n = 1) 410 AMP-CIP-ETP-FOT-NAL
blaOXA-181, qnrS1 Plasmid IncX3, 51-kb
None Plasmid IncI1, 88-kbf
GyrA (Ser83Leu, 
Asp87Asn); ParC (Ser80Ile) Chromosome
AR144.2 (n = 1) 410 AMP-CIP-ETP-FOT-NAL-TET
blaOXA-181, qnrS1 Plasmid IncX3, 51-kb
blaTEM-1B, tet(A) Plasmid IncI1, 98-kbf
GyrA (Ser83Leu, 
Asp87Asn); ParC (Ser80Ile) Chromosome
AMP: ampicillin; CHL: chloramphenicol; CIP: ciprofloxacin; COL: colistin; ETP: ertapenem; FEP: cefepime; FOT: cefotaxime; GEN: gentamicin; 
IMI: imipenem; MERO: meropenem; NAL: nalidixic acid; SMX: sulfamethoxazole; ST: sequence type; TAZ: ceftazidime; TET: tetracycline; 
TGC: tigecycline; TMP: trimethoprim.
a Sequence type based on multilocus sequence typing was determined with MLSTtool 2.0.
b Results interpreted according to the EUCAST and CLSI criteria (see Table 1).
c Resistance genes were detected with ResFinder 3.0: blaCMY-42, cephalosporinase CMY-42 gene (resistance to FEP, TAZ); blaOXA-181, 
carbapenemase OXA-181 gene (resistance to AMP, ETP, FOT); qnrS1, DNA gyrase protection gene to fluoroquinolones (low-level resistance 
to fluoroquinolones); blaTEM-1b, β-lactamase TEM-1b gene (resistance to AMP); tet(A), tetracycline efflux gene (resistance to TET); sugE, 
quaternary ammonium compound resistance gene.
d Chromosomal mutations were detected with ResFinder 3.0. GyrA (Ser83Leu and Asp87Asn), combined with ParC (Ser80Ile), mutations in the 
topoisomerase II and IV (high-level resistance to fluoroquinolones).
e Incompatibility groups (Inc) were determined with PlasmidFinder 1.3.
f As determined using plasmid SPAdes (v3.12.0).
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Figure 3
Circular maps of the resistance plasmids pAN-OXA-181 and pAN-CMY-42, Switzerland, May–August 2018 (n = 2)
Repeat of 
insertion
GATAA
Repeat of 
insertion
TTATC
pAN-CMY-42
IncI1
47.003 bp
DR IR DR
AC ¦ CCGTGA...
IR
...GTCACGG ¦ AC
parA
A. B.
1. pAMA1167-OXA-181 
100% Identity
95% Identity
90% Identity
2. pOXA181_14828 
100% Identity
95% Identity
90% Identity
3. pKS22-OXA-181 
100% Identity
95% Identity
90% Identity
4. pEc31346-OXA-181  
100% Identity
95% Identity
90% Identity
5. pSTIB 
100% Identity
95% Identity
90% Identity
6. pEC21-OXA-181  
100% Identity
95% Identity
90% Identity
1. pCMY42_M217 
100% Identity
95% Identity
90% Identity
2. pCMY42_AR_0137 
100% Identity
95% Identity
90% Identity
3. pCARB35_03 
100% Identity
95% Identity
90% Identity
4. pCMY42_WCHEC13-8 
100% Identity
95% Identity
90% Identity
5. pV233-b
100% Identity
95% Identity
90% Identity
6. pIBAC_IncI1_CMY-42
100% Identity
95% Identity
90% Identity
pAN-OXA-181
IncX3
51.479 bp
4
The coloured outer rings indicate regions of homology of the pAN-OXA-181 (GenBank accession number MK416154) and pAN-CMY-42 (GenBank 
acc. no. MK416155) plasmid of strain AR24.2b with other plasmids, based on BLASTn.
Left panel: pAN-OXA-181. The rings from the inner to the outer represent plasmids pAMA1167-OXA-181 (GenBank acc. no. CP024806; 99.99% 
identity, 1 single nucleotide polymorphism (SNP)), pOXA181_14828 (GenBank acc. no. KP400525; 100% identity), pKS22-OXA-181 (GenBank 
acc. no. KT005457; 99.98%, 3 SNP), pEc31346-OXA-181 (GenBank acc. no. KX894452; 99.99% identity, 1 SNP), pSTIB (GenBank acc. no. 
MG570092; 99.99% identity, 1 SNP) and pEC21-OXA-181 (GenBank acc. no. MG893567; 99.99% identity, 1 SNP).
Left panel: pAN-CMY-42. The rings from the inner to the outer represent plasmids pCMY42_M217 (GenBank acc. no. AP019190; 99% identity, 
65% coverage), pCMY42_AR_0137 (GenBank acc. no. CP021882; 100% identity, 68% coverage), pCARB35_03 (GenBank acc. no. CP031656; 
100% identity, 79% coverage), pCMY42_WCHEC13–8 (GenBank acc. no. KP789019; 100% identity, 71% coverage), pV233-b (GenBank acc. no. 
LC056425; 99% identity, 46% coverage) and pIBAC_IncI1_CMY-42 (GenBank acc. no. KY463221; 100% identity, 78% coverage).
The scale circle shows the coordinates in kbp of each plasmid. Genes are portrayed as coloured blocks in the inner ring of each circular map. 
Genes are coloured according to their classification. Red: antimicrobial resistance genes; dark purple: surface disinfectants resistance genes; 
orange: transposases; fuchsia: genes implicated in replication; green: transfer-associated genes; brown: partition genes; grey: other genes. 
The Δumud and ΔarsR genes are coloured in darker grey, flanking the composite transposon of pAN-OXA-181. The blc gene of pAN-CMY-42 is 
indicated in the map to better represent the composition of the native 4 kb element.
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The dog positive for CP  E. coli  at admission was not 
under antimicrobial treatment at arrival and had no 
previous history of hospitalisation at this clinic, but 
whether it was previously hospitalised in another clinic 
is not known. Nor was it the first animal tested positive 
during the study period. This dog was still positive at 
discharge (Figure 1). 
The demographics, hospitalisation details and antimi-
crobial treatments of the CP E. coli-carrying animals are 
summarised in Table 1. Animals were presented to the 
emergency service of the hospital with a wide range of 
complaints. All cats and 13 of the 17 dogs spent time in 
the intensive care unit of the hospital. The majority of 
dogs (14/17) and cats (3/4) were treated with antimi-
crobials during their hospitalisation; however, none of 
them received carbapenems.
Follow-up samples were obtained within 36 to 101 
days after discharge from 12 of 21 CP  E. coli-positive 
animals. The other nine animals could not be retested 
because they had died (n = 3), or because the own-
ers withdrew their participation in the study (n = 6). 
Two cats still carried CP  E. coli  36 days and 99 days 
after discharge (Figure 1). Seven of the 12 animals that 
underwent a first follow-up could be retested for a sec-
ond time within a time interval of 109 to 166 days after 
discharge of the clinic, including the two cats that were 
still positive after the first follow-up. None of them 
were found to be shedding CP  E. coli  at the second 
follow-up (Figure 1).
Phylogenetic analyses
All 24 CP  E. coli  detected in this study belonged to 
ST410. Analysis of the 24 strains using cgMLST con-
firmed that they were all highly related, all clustering 
in the same branch of the phylogenetic tree, in contrast 
to the sequences of seven other and independent  E. 
coli  ST410 from animal, environmental and human 
origin. The most closely related strain was a canine E. 
coli  isolated in the UK in 2018, which carried the car-
bapenemase gene  bla  NDM-5, the plasmid-mediated 
AmpC (pAmpC) cephalosporinase gene  bla  CMY-42, and 
the β-lactamase gene  bla  TEM-190  [16] (GenBank acces-
sion number CP031653) (Figure 2).
Antimicrobial resistance profile of the 
carbapenemase-producing E. coli
All CP  E. coli  exhibited the same antimicrobial 
resistance profile; they were non-susceptible to 
ampicillin, cefepime, cefotaxime, ceftazidime, cipro-
floxacin, ertapenem and nalidixic acid, except for one 
isolate (AR144.2) which was susceptible to ceftazidime 
and resistant to tetracycline (Table 2).
All isolates carried the carbapenemase gene bla OXA-181, 
which has been associated with a low level of resist-
ance to carbapenems [4,17]. The isolates had MICs 
below the resistance breakpoints set by EUCAST for 
imipenem and meropenem but were resistant to ertap-
enem, with MICs above the resistance breakpoint 
(Table 2). All isolates also contained the  qnrS1  gene 
encoding a DNA gyrase protection protein which con-
fers low-level resistance to fluoroquinolones, as well 
as a serine to leucine substitution at position 83 and 
an aspartic acid to asparagine substitution at position 
87 in GyrA, and a serine to isoleucine substitution at 
position 80 in ParC. These amino acid substitutions are 
known to confer high-level resistance to fluoroquinolo-
nes in E. coli [1].
The pAmpC cephalosporinase bla CMY-42 was also found 
in all isolates, except in the two isolates (AR89.2b and 
AR144.2) which were not resistant to cefepime and 
ceftazidime. The tetracycline resistance found only in 
AR144.2 was associated with the tetracycline efflux 
gene tet(A). This isolate was also the only one that con-
tained the bla TEM-1B β-lactamase gene (Table 3).
Characterisation of the plasmids containing 
resistance genes
The  bla  OXA-181  and  qnrS1  genes were co-localised 
on a 51 kb IncX3 plasmid (pAN-OXA-181) in strain 
AR24.2b (Figure 3). Plasmid mapping showed that all 
other 23 isolates also harboured this same plasmid. 
Plasmid pAN-OXA-181 was > 99.9% similar to other 
IncX3 plasmids from human  E. coli  strains in China 
(pOXA181_14828 and pEC21-OXA-181 [18,19], Denmark 
(pAMA1167-OXA-181) [20], and Lebanon (pSTIB) [21], 
as well as from a porcine  E. coli  strain in Germany 
(pEc31346-OXA-181) [22]. Plasmid pAN-OXA-181 dif-
fered by 3 SNPs from pKS22-OXA-181 which was 
detected in a  Klebsiella variicola  isolated from fresh 
vegetables imported into Switzerland [23] (Figure 3).
Both bla OXA-181 and qnrS1 were found within a compos-
ite transposon in pAN-OXA-181, which was integrated 
between umuD and asrR, similarly to pOXA-181_14828 
[18]. The composite transposon was flanked by two 
copies of the insertion sequence IS26 which were ori-
ented in the same direction. Two 50 bp inverted repeats 
IRL and IRR, each preceded by a 2 bp AC direct repeat, 
were found at both ends of the IS26-flanked composite 
transposon, which is indicative of a transposition event 
[19]. Plasmid pAN-OXA-181 also contained the replica-
tion gene  repB  and a 23 kb transfer region containing 
the  virB1–2–4–5–6–8–9–10–11,  traG  and  trmB  genes 
(Figure 3).
Strain AR24.2b also contained a 47 kb IncI1 plas-
mid (pAN-CMY-42) which harboured the pAmpC 
gene bla CMY-42 (Figure 3). The bla CMY-42 gene is commonly 
found in plasmids within a 4 kb element composed by 
ISEcp1, an outer membrane lipoprotein gene  blc  and 
a quaternary ammonium compound (QAC) resistance 
gene sugE (ISEcp1 – bla CMY-42 – blc – sugE) [24]. In pAN-
CMY-42 however, ΔISEcp1 of this element was split by 
the insertion of a copy of IS1, and subsequent homol-
ogous recombination with another copy of IS1  led to 
its modified structure, as previously described [24]. 
This recombination is supported by the inversion of 
the insertion repeats (GATAA and TTATC) (Figure 3). 
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Plasmid pAN-CMY-42 also contains the replication 
gene  repA  and transfer genes  traA, traE, traJ, traI, 
traY and trbA.
Plasmid pAN-CMY-42 differed from other CMY-42-
containing IncI1 plasmids by its size and structure. The 
most closely related IncI1 CMY-42 plasmids deposited 
so far in GenBank were larger than pAN-CMY-42 by 
1–50 kb, including plasmids isolated from canine  E.
coli  in the UK (pCARB35_03) [16], human patients 
in Myanmar (pCMY42_M217) [25], China (pCMY42_
WCHEC13–8) [24] and Italy (pIBAC_IncI1_CMY-42) [26], 
as well as from  E. coli  isolated from the environment 
(pV233-b) [27], and from an unknown source (pCMY42_
AR_0137 (Figure 3).
Plasmid mapping of the other 23  E. coli  showed that 
21 isolates also contained this same plasmid (pAN-
CMY-42), whereas the two isolates AR89.2 and AR144.2 
lacked the 4 kb element (ISEcp1 – bla  CMY-42  – blc – 
sugE) on their IncI1 plasmid.
Plasmids pAN-OXA-181, pAN-CMY-42 and the chro-
mosome of  E. coli  strain AR24.2b have been depos-
ited in GenBank under accession numbers MK416154, 
MK416155 and CP035944, respectively.
Discussion
Surveillance of enteral carriage of antimicrobial-resist-
ant bacteria in dogs and cats before and after hospital-
isation in a companion animal hospital in Switzerland 
revealed the potential role of small animal clinics as 
an underestimated hotspot for acquisition of CP E. coli. 
In the particular situation presented here, almost one 
quarter of the hospitalised animals acquired a specific 
carbapenem-, cephalosporin- and fluoroquinolone-
resistant clone of ST410 within a time span of 1-9 days 
of hospitalisation. The only dog found to be carrier of 
this clone at admission was chronologically not the 
first to be found positive during the study period, indi-
cating that it was not the primary source of this strain. 
It may, however, have contributed to further enhance 
dissemination of the clone into the hospital. Long-term 
carriage beyond 108 days was only documented in one 
cat among the 10 dogs and two cats that were followed 
up. Nevertheless, all 21 animals that returned home 
with CP E. coli posed a potential risk of disseminating 
hospital-acquired CP  E. coli  into the environment and 
possibly to other animals and humans (Figure 4). 
Although the risk of CP Enterobacteriaceae transmis-
sion may be related to their relative abundance in fae-
ces, our study was not set up to quantify the effective 
number of CP Enterobacteriaceae in faeces because it 
used enrichment and selective plates.
This figure shows the results of the screening of 134 
animals at admission to the veterinary hospital and of 
97 animals at discharge. It illustrates the potential risk 
for the environment, humans and other companion ani-
mals with regard to the carriage of CP E. coli by animals 
that have returned to their homes after having acquired 
CP E. coli during hospitalisation.
Figure 4
Screening of companion animals before and after hospitalisation, Switzerland, May–August 2018 (n = 134)
0.75%
134 97
37
21.6%
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It is important to extend screening and detection meth-
ods in veterinary settings and diagnostic laboratories 
to detect such bacteria of medical and public health 
importance [4]. Detection of carbapenemases of the 
OXA-48 family may be challenging because of their 
low hydrolysing activity which specifies low MIC to car-
bapenems [4,5]. Application of low MIC screening val-
ues would allow identifying the OXA-181-producing  E. 
coli  isolates in our study since they exhibited MICs 
higher than the resistance breakpoint of > 0.5 μg/mL for 
ertapenem and higher than the meropenem screening 
cut-off value of > 0.125 μg/mL recommended by EUCAST 
[13].
Phylogenetic analyses of the CP E. coli using 3,778 genes 
of the core genome (cgMLST) confirmed high genetic 
relationship shared among all the  E. coli  isolates of 
ST410 from this study. This sequence type has recently 
been reported as a new emerging international high-
risk clone, non-susceptible to critically important 
antibiotics such as fluoroquinolones, third-generation 
cephalosporins and carbapenems and with the poten-
tial of cross-sectorial transmission between wildlife, 
humans, pets and the environment [28,29]. Escherichia 
coli  ST410 harbouring  bla  OXA-181  was first described in 
human infections in China in 2015 [18], then in Denmark 
in 2017 [20] and in Italy in 2018 [30], but so far it has 
not been reported in humans in Switzerland. These 
previously described human  E. coli  ST410 producing 
OXA-181 clustered into other branches of the cgMLST 
phylogenetic tree than the strain isolated in our 
study, indicating an independent origin. Another CP E. 
coli  ST410 was identified in a dog in the UK in 2018 
[16], GenBank accession number CP031653), empha-
sising the potential of ST410 for dissemination in the 
veterinary setting. This canine  E. coli  ST410 from the 
UK exhibited a slightly different cgMLST clustering and 
contained NDM-5 as carbapenemase rather than OXA-
181. Although the two canine  E. coli  ST410 from the 
UK and Switzerland contained CMY-42 IncI1 plasmids 
which were highly similar, the one from Switzerland 
was lacking a 12 kb region compared with the CMY-42 
IncI1 plasmid of the canine E. coli from the UK.
The present study revealed for the first time an OXA-181-
producing E. coli ST410 associated with hospitalisation 
of companion animals. Carriage of carbapenemase-
producing bacteria has so far not been reported among 
animals in Switzerland, but one study already reported 
OXA-181 in  K. variicola  isolated from imported fresh 
vegetables [23]. The presence of the same plasmid con-
taining  bla  OXA-181  (pAN-OXA-181) in Enterobacteriaceae 
from companion animals, humans and vegetables 
suggest that interspecies transmission of this plas-
mid between  E. coli  and other Enterobacteriaceae is 
very likely. Nevertheless, the origin of the E. coli ST410 
containing the carbapenemase plasmid pAN-OXA-181 
in the veterinary setting is intriguing. Carbapenems are 
not used in this clinic and are therefore not likely to 
be the driving force for the selection and maintenance 
of this carbapenem-resistant  E. coli  ST410. The use of 
fluoroquinolones and β-lactams (Table 1) may have 
contributed to the selection of this ST410 clone or its 
plasmids, since the isolates also exhibited resistance 
to these classes of antimicrobials. That more animals 
were carriers of the CP ST410 clone at discharge than 
at admission as well as the high genetic relatedness of 
all isolates (including the identical plasmids) strongly 
indicate a common source of contamination within the 
hospital. Nevertheless, no cases of infection caused by 
an OXA-181-producing E. coli were revealed in dogs and 
cats during the 7 months following the outbreak using 
the same selective agar plates as those used in this 
study at the diagnostic unit of our institute. Of note, 
this referral hospital faced several cases of infections 
caused by a nosocomial clone of third-generation-
cephalosporin-resistant K. pneumoniae ST11 producing 
the pAmpC DHA in 2010–2013 [31].
As an infection control measure, thorough disinfec-
tion of the hospital environment was performed after 
this outbreak in 2018 using disinfectant without QAC 
since ST410 also contained a QAC resistance gene 
(sugE) on the cephalosporinase plasmid pAN-CMY-42. 
Furthermore, stringent hospital hygiene and environ-
mental cleaning protocols were introduced and a staff 
screening campaign was initiated. Staff training was 
also intensified to improve hand and environmental 
hygiene. The results and the impact of these measures 
are still being analysed and will be part of a follow-up 
study. Although no conclusion can be drawn at this 
stage of the study on the impact of possible colonisa-
tion of the staff or the pet owners, the results indicate 
that companion animals probably disseminated CP 
Enterobacteriaceae via faeces in the environment after 
hospitalisation and may represent a potential risk for 
transmission of CP Enterobacteriaceae to other ani-
mals and humans in the community and a serious One 
Health concern.
This outbreak stresses the need for national routine 
monitoring of carbapenemase-producing bacteria in 
companion animals using a representative sampling 
strategy analogous to the national surveillance of anti-
biotic resistance in food-producing animals at slaugh-
terhouses in Switzerland and the European Union [32]. 
Based on the results of our study, we strongly recom-
mend monitoring hospitalised companion animals for 
CP Enterobacteriaceae carriage at discharge using a 
sampling strategy representative of the number of hos-
pitalised animals in the enrolled clinics. Such a surveil-
lance programme should identify high-risk companion 
animal clinics and improve infection prevention and 
control as well as hygiene standards.
Conclusion
This study provided evidences that dogs and cats can 
acquire CP Enterobacteriaceae within a short time of 
hospitalisation. Even if the colonisation of the ani-
mals did not last longer than 40 days in the majority of 
the animals, shedding of CP Enterobacteriaceae after 
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hospitalisation represents a public health and environ-
mental concern. Early detection and nationwide sur-
veillance of carbapenemase-producing isolates, as well 
as effective infection prevention and control measures, 
need to be implemented in veterinary settings to limit 
the spread of high-risk clones in animals, humans and 
the environment.
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